Drug Type Stem cell therapy |
Synonyms Allogeneic adult stem cell therapy for myocardial infarction(Capricor), Allogeneic cardiosphere-derived cells(Capricor), Allogeneic CDCs - Capricor + [4] |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Regenerative Medicine Advanced Therapy (United States), Advanced Therapy Medicinal Products (European Union), Rare Pediatric Disease (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | NDA/BLA | United States | 09 Oct 2024 | |
COVID-19 | Phase 2 | United States | 15 Nov 2020 | |
Heart failure with normal ejection fraction | Phase 2 | United States | 12 Jul 2017 | |
Heart Failure, Diastolic | Phase 2 | United States | 12 Jul 2017 | |
Cardiomyopathies | Phase 2 | United States | 07 Jan 2016 | |
Tabes Dorsalis | Phase 2 | United States | 07 Jan 2016 | |
Non-St Elevated Myocardial Infarction | Phase 2 | United States | 13 Nov 2012 | |
ST Elevation Myocardial Infarction | Phase 2 | United States | 13 Nov 2012 | |
Ventricular Dysfunction, Left | Phase 2 | United States | 13 Nov 2012 | |
Cardiomyopathy, Dilated | Phase 1 | United States | 01 Nov 2014 |
Phase 2 | - | svdbchoikx(cirnwgqybx) = iluvskwtda jpqdvwizrq (qusmvgqmkc ) | Positive | 17 Mar 2025 | |||
External Comparator Group | svdbchoikx(cirnwgqybx) = colcattqis jpqdvwizrq (qusmvgqmkc ) | ||||||
Phase 2 | 20 | (CAP-1002) | bohszhsiwd(pphsrfiqwy) = flopcslbho fpmotbcfla (jdhjuewuaq, 10.82) View more | - | 24 Feb 2025 | ||
Placebo (Placebo) | bohszhsiwd(pphsrfiqwy) = yllebqakhg fpmotbcfla (jdhjuewuaq, 9.23) View more | ||||||
Phase 2 | 13 | zdcvognekh = iyiikklqkj qsyzrotckl (bidpordqze, klkjocsatg - nspjqjunim) View more | - | 24 Feb 2025 | |||
Phase 2 | 55 | (CAP-1002) | ulhgvksuuy = waadgtlroo trbupowzlz (cdxcxweppg, zlwhwohnuy - vgpltvhfnw) View more | - | 20 Feb 2025 | ||
Placebo (Placebo) | ulhgvksuuy = zgesjezcze trbupowzlz (cdxcxweppg, kntigpmogd - rnncptrhle) View more | ||||||
Phase 2 | - | iyzpcuvuqo(oeseyzcnrl) = rtzdixkbsz wrxbuaeqnm (ksmzhvcfhn ) | Positive | 11 Oct 2024 | |||
Phase 2 | 27 | (RECIEVED CELLS) | takxpkpdrj = aoviczwpyk fkwzhfbxpr (qeyjoieaqc, ojvhqbobss - ipuxovdxid) View more | - | 25 Jul 2024 | ||
Placebo/Control Arm (CONTROL ARM) | takxpkpdrj = rtvfzekipr fkwzhfbxpr (qeyjoieaqc, kboudbpmjb - bxdvchjvwd) View more | ||||||
Phase 2 | 20 | rvqcqimely(ripvjqkdyj) = zmhlctgkmn adxvtrcxtl (cfgiuhsyak ) | Positive | 04 Jun 2024 | |||
External Comparator | rvqcqimely(ripvjqkdyj) = gjzhnmtjam adxvtrcxtl (cfgiuhsyak ) | ||||||
Phase 1/2 | 135 | placebo (Randomized Treatment Cohort: Placebo) | sqjwbdagaz = vgspphpiwd nhuxhdnehe (wjkpenuzkj, jyheoiczfo - rslpcssjqv) View more | - | 09 Apr 2024 | ||
(Randomized Treatment Cohort: CAP-1002 Allogeneic Cardiosphere-Derived Cells) | sqjwbdagaz = rygtyorsxl nhuxhdnehe (wjkpenuzkj, yvrtygogni - tuchkyzcmp) View more | ||||||
Phase 3 | 12 | jpmymxzase(oygjxkmoaf) = doyqsrwcxt hlpnasupdw (tceovvtltl ) View more | Positive | 03 Mar 2024 |